SEC Form 4 · accession 0000899243-16-035555
INFINITY PHARMACEUTICALS, INC. · INFI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sujay Kango
Officer — Chief Commercial Officer
Period of report
Dec 12, 2016
Accepted (ET)
Dec 14, 2016 · 5:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001113148
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 12, 2016 | S | 25,009 | $1.304 | D | 50,590 | D | |
| Common Stock | Dec 13, 2016 | S | 298 | $1.30 | D | 50,292 | D | |
| Common Stock | Dec 13, 2016 | S | 42,017 | $1.2673 | D | 8,275 | D | |
| Common Stock | Dec 13, 2016 | S | 7,676 | $1.2537 | D | 599 | D | |
| Common Stock | holding | — | — | — | 3,598 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.30 to $1.31, inclusive. The reporting person undertakes to provide to Infinity Pharmaceuticals, Inc., any security holder of Infinity Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 1.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.26 to $1.285, inclusive. The reporting person undertakes to provide to Infinity Pharmaceuticals, Inc., any security holder of Infinity Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.25 to $1.255, inclusive. The reporting person undertakes to provide to Infinity Pharmaceuticals, Inc., any security holder of Infinity Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3.
Remarks
Ex. 24: Limited Power of Attorney